ALK and non-small cell lung carcinoma: Ironically, unlike the oncoproteins EGFR and ALK, which are less prevalently altered in NSCLC, there are few targeted therapies for KRAS-mutant NSCLC, and few clinical studies have specifically addressed this largest NSCLC subpopulation (6, 7).